Pathological Changes After Autologous Formalin-Fixed Tumor Vaccine Therapy Combined With Temozolomide for Glioblastoma : Three Case Reports

Access this Article

Search this Article

Author(s)

    • SAKAMOTO Noriaki
    • Department of Neurosurgery, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • ISHIKAWA Eiichi
    • Department of Neurosurgery, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • YAMAMOTO Tetsuya
    • Department of Neurosurgery, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • SATOMI Kaishi
    • Department of Pathology, Institute of Basic Medical Sciences, University of Tsukuba
    • NAKAI Kei
    • Department of Neurosurgery, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • SATO Masayuki
    • Department of Neurosurgery, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • MORISHITA Yukio
    • Department of Pathology, Institute of Basic Medical Sciences, University of Tsukuba
    • TAKANO Shingo
    • Department of Neurosurgery, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • OHNO Tadao
    • Advanced Research Institute for Science and Engineering, Waseda University
    • TSUBOI Koji
    • Department of Proton Medical Research Center, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • MATSUMURA Akira
    • Department of Neurosurgery, Graduate School of Comprehensive Human Sciences, University of Tsukuba

Abstract

Temozolomide (TMZ), an alkylating agent widely used for patients with glioblastoma multiforme (GBM), has the potential to enhance the acquired immune response to GBM. Here, we describe 3 cases of GBM patients treated with autologous formalin-fixed tumor vaccine (AFTV) combined with TMZ. All cases demonstrated pathological changes associated with the therapy. After a 4-week break from the standard initial treatments, 1 patient with primary GBM and 2 patients with secondary GBM received adjuvant TMZ for 5 days combined with AFTV injection and were subsequently treated with multiple cycles of adjuvant TMZ for 5 days every 28 days (AFTV/TMZ therapy). Adverse effects related to AFTV plus TMZ were very minor in all patients. Magnetic resonance imaging revealed partial response in 2 patients. CD3<sup>+</sup>CD8<sup>+</sup> lymphocytes were frequently detected in surgical specimens and MIB-1 labeling index in 2 cases decreased after AFTV/TMZ therapy. AFTV/TMZ therapy is suitable for larger scale clinical trials.<br>

Journal

  • Neurologia medico-chirurgica

    Neurologia medico-chirurgica 51(4), 319-325, 2011-04-15

    The Japan Neurosurgical Society

References:  23

Codes

  • NII Article ID (NAID)
    10028105397
  • NII NACSIS-CAT ID (NCID)
    AN00358613
  • Text Lang
    ENG
  • Article Type
    NOT
  • ISSN
    04708105
  • Data Source
    CJP  J-STAGE 
Page Top